Proactive Investors - Run By Investors For Investors

Imugene to present cancer vaccine research at AACR annual meeting

The company has multiple B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies.
Imugene to present cancer vaccine research at AACR annual meeting
Imugene is a clinical stage immune-oncology company

Imugene Limited (ASX:IMU) scientific advisor Professor Ursula Wiedermann is to present on the company’s HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 annual meeting.

Wiedermann is the co-inventor of HER-Vaxx and also a member of Imugene’s scientific advisory board.

 

The presentation is authored by Wiedermann and researchers at the Medical University of Vienna in Australia and Imugene.

Its title is ‘A phase1b open label multi-centre study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/neu overexpressed advanced cancer of the stomach.

READ: Imugene targets defender B-cells with cancer vaccines HER-Vaxx and B-Vaxx

Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The immunotheraphy is constructed from several B cell epitopes derived from the extracellular domain of HER2/neu.

It has been show in pre-clinical studies and phase-one studies to stimulate a potent polyclonal antibody response to HER2/neu, a well-known and validated cancer target.

READ: Imugene has cancer vaccine trial data published in prestigious medical journal

The company recently had its phase-one clinical trial data for its B cell cancer vaccine B-Vaxx published in the prestigious AACR journal Clinical Cancer Research.

The article was primarily authored by Imugene’s scientific advisory board members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

1550850611_CancerHeadline.jpg
February 23 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
picture of a knee
May 21 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
seeds in a bowl
March 08 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use